Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 23 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-9.06 Insider Own2.60% Shs Outstand1.64M Perf Week38.87%
Market Cap1.31M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float1.60M Perf Month23.25%
Income-97.58M PEG- EPS next Q-1.03 Inst Own12.30% Short Float12.09% Perf Quarter-70.04%
Sales0.00M P/S- EPS this Y- Inst Trans411.44% Short Ratio0.19 Perf Half Y-84.92%
Book/sh15.85 P/B0.05 EPS next Y- ROA-509.33% Short Interest0.19M Perf Year-98.96%
Cash/sh0.96 P/C0.83 EPS next 5Y- ROE-2268.91% 52W Range0.50 - 96.95 Perf YTD-11.00%
Dividend Est.- P/FCF- EPS past 5Y- ROI-495.26% 52W High-99.17% Beta0.13
Dividend TTM- Quick Ratio0.17 Sales past 5Y0.00% Gross Margin- 52W Low60.20% ATR (14)0.10
Dividend Ex-Date- Current Ratio0.17 EPS Y/Y TTM-379.26% Oper. Margin0.00% RSI (14)61.85 Volatility24.92% 13.18%
Employees14 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price14.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q-303.89% Payout- Rel Volume5.40 Prev Close0.62
Sales Surprise- EPS Surprise43.75% Sales Q/Q- EarningsNov 14 AMC Avg Volume1.01M Price0.80
SMA2033.40% SMA5011.69% SMA200-85.16% Trades Volume5,468,151 Change29.13%
Feb-22-24 07:47AM
Feb-14-24 07:53AM
Feb-07-24 08:02AM
Jan-31-24 07:57AM
Jan-24-24 07:57AM
01:31PM Loading…
Jan-17-24 01:31PM
Jan-10-24 08:06AM
Jan-04-24 07:50AM
Jan-03-24 08:07AM
Dec-18-23 08:12AM
Dec-14-23 07:01AM
Dec-07-23 11:20AM
Dec-06-23 09:00PM
09:54AM Loading…
Nov-30-23 11:30AM
Nov-14-23 04:35PM
Nov-09-23 07:35AM
Nov-06-23 07:05AM
Nov-01-23 08:07AM
Oct-25-23 06:50AM
Oct-18-23 07:05AM
Oct-11-23 07:05AM
Oct-04-23 07:05AM
Sep-27-23 07:07AM
Sep-22-23 06:35AM
Sep-12-23 06:30AM
Aug-21-23 04:15PM
08:00AM Loading…
Jul-24-23 08:00AM
Jul-17-23 07:38AM
Jul-14-23 07:37AM
Jul-10-23 07:37AM
Jul-07-23 07:37AM
Jun-28-23 07:37AM
Jun-20-23 04:07PM
Jun-13-23 08:07AM
Jun-06-23 09:07AM
May-25-23 09:07AM
May-19-23 04:15PM
May-15-23 09:07AM
May-12-23 09:07AM
May-11-23 09:07AM
May-09-23 09:05AM
May-04-23 09:07AM
May-01-23 06:30PM
Apr-27-23 09:07AM
Apr-26-23 09:10AM
Apr-25-23 09:07AM
Apr-24-23 09:07AM
Apr-19-23 09:07AM
Apr-13-23 09:07AM
Apr-12-23 09:07AM
Apr-11-23 09:07AM
Apr-10-23 09:07AM
Apr-03-23 09:05AM
Mar-13-23 04:30PM
Mar-07-23 09:20AM
Mar-01-23 09:20AM
Feb-27-23 09:20AM
Feb-23-23 09:20AM
Jan-27-23 04:00PM
Jan-25-23 09:45AM
Jan-11-23 02:45PM
Jan-05-23 09:45AM
Jan-03-23 09:45AM
ZyVersa Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It leverages advanced & proprietary technologies to develop product candidates in the areas of renal and inflammatory diseases. The company was founded by Stephen C. Glover in 2014 and is headquartered in Weston, FL.